Fig. 4From: Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritisModified cumulative distribution curves of changes in FACIT-Fatigue score at week 24 in a DISCOVER-1 and b DISCOVER-2Back to article page